AstraZeneca, Merck Ink Licensing Deal - Analyst Blog

By
A A A

AstraZeneca ( AZN ) recently entered into a worldwide licensing agreement with Merck & Co. Inc. ( MRK ) for MK-1775, an oral small molecule inhibitor of WEE1 kinase. MK-1775 is being developed for the treatment of patients with P53-deficient ovarian cancer (phase IIa).

As per the terms of the deal, AstraZeneca will make an upfront payment of $50 million to Merck. Apart from this Merck will also be eligible to receive development and regulatory milestone payments, sales-related payments and tiered royalties on net sales of MK-1775, on approval. AstraZeneca will undertake all future development, manufacturing and marketing responsibilities.

This deal is in line with AstraZeneca's strategy of boosting its pipeline by acquiring candidates. Generic competition has been adversely impacting AstraZeneca's revenues over the past few quarters. This has put significant pressure on the company.

In a bid to add late-stage candidates to its pipeline, AstraZeneca entered into a number of acquisition deals (Pearl Therapeutics and Omthera Pharmaceuticals) in the last few months and agreements with companies such as FibroGen, Inc.

We believe the licensing of MK-1775 makes strategic sense. With this acquisition, AstraZeneca will strengthen its oncology pipeline. Last month, AstraZeneca entered into an agreement to acquire privately-held U.S. based company, Amplimmune. The acquisition will add oncology candidates such as AMP-224 (phase Ib) and AMP-514 (late-stage pre-clinical trial with investigational new drug filing planned by year end) to AstraZeneca's pipeline.

AstraZeneca currently carries a Zacks Rank #4 (Sell). At present, companies like Novo Nordisk ( NVO ) and Bayer ( BAYRY ) look well-positioned with a Zacks Rank #2 (Buy).



ASTRAZENECA PLC (AZN): Free Stock Analysis Report

BAYER A G -ADR (BAYRY): Free Stock Analysis Report

MERCK & CO INC (MRK): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AZN , BAYRY , MRK , NVO

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

How to Fire Your Adviser
How to Fire Your Adviser            

Stocks

Referenced

50%
88%
100%

Most Active by Volume

75,750,465
  • $16.77 ▲ 0.36%
59,791,760
  • $101.58 ▲ 0.71%
38,720,669
  • $42.59 ▼ 0.28%
37,416,417
  • $46.52 ▼ 0.51%
35,101,793
  • $16.28 ▲ 0.74%
34,987,975
  • $99.53 ▲ 0.15%
33,760,830
  • $3.63 ▲ 0.69%
32,148,671
  • $17.61 ▲ 0.57%
As of 9/17/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com